tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2023 Jun 6;10(6)
fad306.
doi: 10.1093/ofid/ofad306. eCollection 2023 Jun. Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer
Catherine Liu[SUP] 1 2 3 [/SUP], Leah H Yoke[SUP] 1 2 [/SUP], Pooja Bhattacharyya[SUP] 1 2 [/SUP], Ryan D Cassaday[SUP] 3 4 [/SUP], Guang-Shing Cheng[SUP] 3 5 [/SUP], Zahra Kassamali Escobar[SUP] 1 6 [/SUP], Cristina Ghiuzeli[SUP] 3 4 [/SUP], Denise J McCulloch[SUP] 1 2 3 [/SUP], Steven A Pergam[SUP] 1 2 3 [/SUP], Pavitra Roychoudhury[SUP] 1 7 [/SUP], Frank Tverdek[SUP] 1 6 [/SUP], Joshua T Schiffer[SUP] 1 2 3 [/SUP], Emily S Ford[SUP] 1 2 [/SUP]
Affiliations
Persistent symptomatic coronavirus disease 2019 (COVID-19) is a distinct clinical entity among patients with hematologic cancer and/or profound immunosuppression. The optimal medical management is unknown. We describe 2 patients who had symptomatic COVID-19 for almost 6 months and were successfully treated in the ambulatory setting with extended courses of nirmatrelvir-ritonavir.
Keywords: extended nirmatrelvir-ritonavir; hematologic cancer; persistent COVID-19.
. 2023 Jun 6;10(6)
fad306.doi: 10.1093/ofid/ofad306. eCollection 2023 Jun. Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer
Catherine Liu[SUP] 1 2 3 [/SUP], Leah H Yoke[SUP] 1 2 [/SUP], Pooja Bhattacharyya[SUP] 1 2 [/SUP], Ryan D Cassaday[SUP] 3 4 [/SUP], Guang-Shing Cheng[SUP] 3 5 [/SUP], Zahra Kassamali Escobar[SUP] 1 6 [/SUP], Cristina Ghiuzeli[SUP] 3 4 [/SUP], Denise J McCulloch[SUP] 1 2 3 [/SUP], Steven A Pergam[SUP] 1 2 3 [/SUP], Pavitra Roychoudhury[SUP] 1 7 [/SUP], Frank Tverdek[SUP] 1 6 [/SUP], Joshua T Schiffer[SUP] 1 2 3 [/SUP], Emily S Ford[SUP] 1 2 [/SUP]
Affiliations
- PMID: 37383248
- PMCID: PMC10296060
- DOI: 10.1093/ofid/ofad306
Persistent symptomatic coronavirus disease 2019 (COVID-19) is a distinct clinical entity among patients with hematologic cancer and/or profound immunosuppression. The optimal medical management is unknown. We describe 2 patients who had symptomatic COVID-19 for almost 6 months and were successfully treated in the ambulatory setting with extended courses of nirmatrelvir-ritonavir.
Keywords: extended nirmatrelvir-ritonavir; hematologic cancer; persistent COVID-19.